Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets

Informations

• Publié par: frost-sullivan
• Nombre de lectures: 4
• Langue: English

Extrait

Frost & Sullivan: Expanding Sample Prep

Market Supports Growth Trends in Molecular

Diagnostics Markets

PR Newswire

MOUNTAIN VIEW, California, June 21, 2012

- Biomarker validation analyses create surge in demand for formalin-

fixed, paraffin-embedded sample prep solutions

MOUNTAIN VIEW, California

,

June 21, 2012

/PRNewswire/ -- Hundreds of millions

of formalin-fixed, paraffin-embedded (FFPE) archive specimens available

globally have piqued tremendous interest for biomarker validation studies,

generating a surge in demand for FFPE sample prep solutions. FFPE archive

specimens from patients with known clinical outcomes provide an economic

and readily available source for the biomarker validation needed to develop

clinical molecular cancer tests.

Analysis from Frost & Sullivan's (http://www.clinicaldiagnostics.frost.com)

Demand Analysis of U.S. Cancer Sample Prep Market

research finds that

automated sample prep systems developed specifically for FFPE provide

greater sample throughput and satisfy the requirements of various end users.

If you are interested in more information on this research, please send an

email to Britni Myers, Corporate Communications, at [e-mail],

with your full name, company name, job title, telephone number, company

email address, company website, city, state and country.

Archived tissues are Institutional Review Board (IRB) exempt and are a feasible

alternative to validating biomarkers when compared to costly prospective

clinical trials. Therefore, pharmaceutical companies and research institutes are

employing FFPE services for their pharmacogenomics programs.

"Translational research using FFPE archive specimens is helping to produce an

expanding menu of future molecular-based cancer testing," said Frost &

Sullivan Industry Analyst Winny Tan. "A Frost & Sullivan survey of molecular

pathology labs in

the United States

reveals that nucleic acid extraction from

FFPE specimens is poised for more than 20 percent volume growth in the next

three years."

Molecular sample prep vendors have offered kits for FFPE specimens for the

last three to five years. Process automation signals the brink of a market

expansion fueled by the increased throughput. Additionally, clinical molecular

tests for serine/threonine-protein kinase B-Raf (BRAF) and GTPase Kras (KRAS)

gene biomarkers, as well as for epidermal growth factor receptor (EGFR), are

driving the demand for the FFPE sample preps.

Sample prep for FFPE specimens that produce nucleic acid extractions of high

purity and yield will become even more critical for downstream molecular

testing. The clinical labs surveyed by Frost & Sullivan anticipate an inevitable

integration of molecular extraction techniques with the long FFPE legacy that

exists in solid tumor diagnostics.

However, growth of this market is hindered by the limited number of sites

where molecular pathology is performed as well as the slow adoption of FFPE

sample prep automation by hospital laboratories. Further, hospital budgets are